JPRN-UMIN000001414已完成2 期
Feasibility study of S-1 as additional therapy after neo-adjuvant or adjuvant chemotherapy for triple negative breast cancer(SBCCSG-14). - Feasibility study of S-1 as additional therapy after neo-adjuvant or adjuvant chemotherapy for triple negative breast cancer(SBCCSG-14).
Saitama Breast Cancer Clinical Study Group(SBCCSG)0 个研究点目标入组 60 人开始时间: 2008年10月6日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Either of ER, PgR, HER2 is positive by surgical specimen. 2) Male breast cancer 3) Severe complications (uncontrolled diabetes mellitus, infection, heart failure which needs medical treatment (unstable angina pectoris, history of myocardial infarction occurred within 6 months), mental disorder) 4) Interstitial lung disease, pulmonary fibrosis 5) History of serious drug allergy 6) Active other malignancies 7) During pregnancy or lactation 8) History of hypersensitivity 9) History of serious hypersensitivity to fluoropyrimidines 10) During administration of fluoropyrimidines 11) During administration of flucytosine 12) Patients judged inappropriate by physicians
研究者
相似试验
招募中
2 期
Feasibility study of combination therapy with S-1 plus irinotecan in patients with EGFR positive KRAS mutation type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine, bevacizumabColorectal cancerJPRN-UMIN0000097343rd department of surgery Tokyo Medical University25
已完成
不适用
Phase II trial of S-1 therapy for advanced or recurrent esophageal cancer resistant or intolerable existing treatmentsesophageal cancerJPRN-UMIN000023736Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine50
已完成
不适用
Feasibility of adjuvant treatment with S-1 and oxaliplatin in patients with resectable esophageal canceresophageal cancerNL-OMON47475Academisch Medisch Centrum40
已完成
2 期
Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901).Colorectal cancerJPRN-UMIN000002475Kyushu Study group of Clinical Cancer39
进行中（未招募）
1 期
A Phase II Pilot Study to Assess Safety and Efficacy of Sodium Valproate in Adults with McArdle DiseaseMcArdle disease (Glycogen storage disease type V, GSDV). The condition is an inherited disorder of skeletal muscle that causes exercise intolerance. The condition can give way to potential rhabdomyolysis which can cause acute renal failure and from middle age muscle wasting and weakness. Affected patients are unable to produce lactate during ischaemic exercise due to a congenital lack of the enzyme muscle glycogen phosphorylase which is essential for glycogen metabolism.MedDRA version: 16.1 Level: LLT Classification code 10026969 Term: McArdle's disease System Organ Class: 100000004850EUCTR2012-002933-12-GBniversity College London,8